OneSource Specialty Pharma shares rose nearly 14% after the company reported Q2 revenue growth of 37% year-on-year and adjusted profit after tax of ₹93.7 crore. The company maintained its FY28 targets and expects expanded drug-device combination capacity to support future growth.